Oncology Corporate Profile
Otsuka America Pharmaceutical, Inc. (OAPI) is part of the Otsuka Group (Otsuka). OAPI was established in the U.S. in 1989 and is responsible for all pharmaceutical and medical device commercial activities in North America.
|Busuflex®||busulfan||Busuflex® (busulfan) Injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.|
|Sprycel®||dasatinib||Sprycel® is a kinase inhibitor indicated for:|
• treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib.
• treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
View additional information on commercial products here »
|Brand / Product||Class||Area of Study||Phase||Partnership|
|AT13387||HSP90 inhibitor||2nd line metastatic Gastrointestinal Stromal Tumors (GIST)||II|
|SGI-110||DNA methyltransferase inhibitor||Acute Myelogenous Leukemia (AML)||II|
|AT7519||CDK inhibitor||Chronic Lymphocytic Leukemia (CLL)||II||Novartis|
|AT7519||CDK inhibitor||Mantel Cell Lymphoma (MCL)||II||Novartis|
|AT9283||Aurora/JAK2 inhibitor||Multiple Myeloma||II|
|AT7519 (+ bortezomib)||CDK inhibitor||Multiple Myeloma||II||Novartis|
|SGI-110||DNA methyltransferase inhibitor||Myelodysplastic Syndrome (MDS)||II|
|AT13387||HSP90 inhibitor||Non Small Cell Lung Cancer (NSCLC)||II|
|AT13387||HSP90 inhibitor||2nd line metastatic castrate-resistant prostate cancer (CRPC)||I|
|OPB 51602||stat3 inhibitor||Various cancer types||I|
|AT7519||CDK inhibitor||Various cancer types||I||Novartis|
|LEE011||CDK4 inhibitor||Various cancer types||I||Novartis|
|AZD5363||PKB/Akt inhibitor||Various cancer types||I||AstraZeneca|
|AT9283||Aurora/JAK2 inhibitor||Various cancer types||I|
View additional information on product candidates here »